24.09 USD
+0.06 (+0.25%)
24.09 USD
0 (0%)
CAI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 535 industry peers in the Biotechnology industry. While CAI seems to be doing ok healthwise, there are quite some concerns on its profitability. CAI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CAI had negative earnings in the past year.
In multiple years CAI reported negative net income over the last 5 years.
In multiple years CAI reported negative operating cash flow during the last 5 years.
1.2 Ratios
CAI has a worse Return On Assets (-101.38%) than 74.95% of its industry peers.
Looking at the Return On Equity, with a value of -208.66%, CAI is doing worse than 67.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.38% | ||
| ROE | -208.66% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 53.54%, CAI is in the better half of the industry, outperforming 75.70% of the companies in the same industry.
CAI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CAI has about the same amount of shares outstanding.
CAI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CAI has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.16 indicates that CAI is not in any danger for bankruptcy at the moment.
CAI has a Altman-Z score of 5.16. This is in the better half of the industry: CAI outperforms 75.33% of its industry peers.
CAI has a Debt/Equity ratio of 0.79. This is a neutral value indicating CAI is somewhat dependend on debt financing.
CAI has a Debt to Equity ratio of 0.79. This is in the lower half of the industry: CAI underperforms 74.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.16 |
ROIC/WACCN/A
WACC8.91%
2.3 Liquidity
A Current Ratio of 9.93 indicates that CAI has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.93, CAI belongs to the best of the industry, outperforming 80.93% of the companies in the same industry.
A Quick Ratio of 9.36 indicates that CAI has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 9.36, CAI belongs to the best of the industry, outperforming 80.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.93 | ||
| Quick Ratio | 9.36 |
3. Growth
3.1 Past
CAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.22%, which is quite good.
CAI shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.67%.
CAI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.64% yearly.
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -16.24% on average over the next years. This is quite bad
CAI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.62% yearly.
EPS Next Y-136.46%
EPS Next 2Y-79.95%
EPS Next 3Y-46.01%
EPS Next 5Y-16.24%
Revenue Next Year63.34%
Revenue Next 2Y54.33%
Revenue Next 3Y43.5%
Revenue Next 5Y30.62%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 85.57 indicates a quite expensive valuation of CAI.
Based on the Price/Forward Earnings ratio, CAI is valued cheaper than 87.48% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.46, CAI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 85.57 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CAI's earnings are expected to decrease with -46.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-79.95%
EPS Next 3Y-46.01%
5. Dividend
5.1 Amount
No dividends for CAI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.09
+0.06 (+0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners35.5%
Inst Owner Change12.71%
Ins Owners48.84%
Ins Owner Change9.52%
Market Cap6.77B
Revenue(TTM)931.41M
Net Income(TTM)-998.17M
Analysts86.67
Price Target40.16 (66.71%)
Short Float %3.63%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1853.44%
Min EPS beat(2)-3845.54%
Max EPS beat(2)138.66%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)28.77%
Min Revenue beat(2)26.17%
Max Revenue beat(2)31.38%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.64%
PT rev (3m)2.42%
EPS NQ rev (1m)24.09%
EPS NQ rev (3m)23.11%
EPS NY rev (1m)1.84%
EPS NY rev (3m)-67.72%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)2.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 85.57 | ||
| P/S | 7.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 14.16 | ||
| P/tB | 14.76 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.58
EYN/A
EPS(NY)0.28
Fwd EY1.17%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.31
BVpS1.7
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.38% | ||
| ROE | -208.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.54% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.93 | ||
| Quick Ratio | 9.36 | ||
| Altman-Z | 5.16 |
F-ScoreN/A
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-136.46%
EPS Next 2Y-79.95%
EPS Next 3Y-46.01%
EPS Next 5Y-16.24%
Revenue 1Y (TTM)34.67%
Revenue growth 3YN/A
Revenue growth 5Y6.64%
Sales Q2Q%N/A
Revenue Next Year63.34%
Revenue Next 2Y54.33%
Revenue Next 3Y43.5%
Revenue Next 5Y30.62%
EBIT growth 1Y19.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.94%
EBIT Next 3Y48.79%
EBIT Next 5Y40.45%
FCF growth 1Y15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.19%
OCF growth 3YN/A
OCF growth 5YN/A
CARIS LIFE SCIENCES INC / CAI FAQ
What is the fundamental rating for CAI stock?
ChartMill assigns a fundamental rating of 4 / 10 to CAI.
What is the valuation status of CARIS LIFE SCIENCES INC (CAI) stock?
ChartMill assigns a valuation rating of 6 / 10 to CARIS LIFE SCIENCES INC (CAI). This can be considered as Fairly Valued.
Can you provide the profitability details for CARIS LIFE SCIENCES INC?
CARIS LIFE SCIENCES INC (CAI) has a profitability rating of 2 / 10.
What is the expected EPS growth for CARIS LIFE SCIENCES INC (CAI) stock?
The Earnings per Share (EPS) of CARIS LIFE SCIENCES INC (CAI) is expected to decline by -136.46% in the next year.